Back to Authors

Carnevalli, Larissa S

0000-0001-7432-0195

Mayo Clinic

BioScience, Oncology R&D, AstraZeneca, Cambridge, UK.

Citations 1

A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies

Leukemia & Lymphoma | July 16, 2021 | Volume: 62 | Issue: 11 | Pages: 2625-2636

10.1080/10428194.2021.1938027 | PMID 34269152